Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

Suppr

超能文献

作者信息

Nguyen Vi, Gurney Howard, van der Poorten David

机构信息

Westmead Hospital, Sydney, New South Wales, Australia.

出版信息

J Clin Oncol. 2011 Jan 10;29(2):e21-3. doi: 10.1200/JCO.2010.30.6522. Epub 2010 Oct 12.

DOI:10.1200/JCO.2010.30.6522

PMID:20940196

Abstract

摘要

相似文献

Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

J Clin Oncol. 2011 Jan 10;29(2):e21-3. doi: 10.1200/JCO.2010.30.6522. Epub 2010 Oct 12.

Prostate cancer and liver dysfunction: a case of cytokine dysregulation.

J Pain Symptom Manage. 2007 Sep;34(3):225-6. doi: 10.1016/j.jpainsymman.2007.05.003. Epub 2007 Jun 21.

Paraneoplastic liver dysfunction in prostate cancer.

J Pain Symptom Manage. 2006 Dec;32(6):511-3. doi: 10.1016/j.jpainsymman.2006.03.015.

Inflammatory prostate cancer: an underestimated paraneoplastic clinical manifestation.

Urol Oncol. 2005 Sep-Oct;23(5):318-22. doi: 10.1016/j.urolonc.2005.04.003.

Acquired color blindness in an elderly male patient from recurrent metastatic prostate cancer.

J Am Geriatr Soc. 2005 Jul;53(7):1265-7. doi: 10.1111/j.1532-5415.2005.53384_6.x.

Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.

J Urol. 1998 Mar;159(3):718-22.

Cytokines levels in prostate adenocarcinomas.

Rom J Morphol Embryol. 2005;46(3):179-82.

[Paraneoplastic syndromes in urology].

Arch Esp Urol. 1991 Oct;44(8):943-9.

Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy.

Br J Dermatol. 2009 Feb;160(2):468-70. doi: 10.1111/j.1365-2133.2008.08982.x. Epub 2008 Dec 11.

Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression.

In Vivo. 2009 Sep-Oct;23(5):827-33.

引用本文的文献

A patient with obstructive jaundice secondary to intrahepatic bleeding caused by prostate cancer metastasis.

Urol Case Rep. 2020 Oct 22;34:101443. doi: 10.1016/j.eucr.2020.101443. eCollection 2021 Jan.

Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature.

Turk J Urol. 2018 Sep 12;45(1):70-72. doi: 10.5152/tud.2018.52059. Print 2019 Nov.

Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome.

Mol Clin Oncol. 2018 Apr;8(4):609-612. doi: 10.3892/mco.2018.1564. Epub 2018 Feb 2.

Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer Aggravated by Steroid Therapy.

Med Princ Pract. 2018;27(2):197-200. doi: 10.1159/000486717. Epub 2018 Jan 10.

Paraneoplastic jaundice and prostate cancer.

BMJ Case Rep. 2017 Apr 22;2017:bcr-2016-218001. doi: 10.1136/bcr-2016-218001.

Hepatic Dysfunction as a Paraneoplastic Manifestation of Metastatic Prostate Adenocarcinoma.

J Investig Med High Impact Case Rep. 2014 Jun 24;2(2):2324709614539927. doi: 10.1177/2324709614539927. eCollection 2014 Apr-Jun.

Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer.

Clin J Gastroenterol. 2014 Jun;7(3):278-82. doi: 10.1007/s12328-014-0484-4. Epub 2014 Apr 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验